OPTN - OptiNose, Inc.
After hours:
Chart Events
Hammer
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.2500 |
| Open | 1.2200 |
| Bid | 1.2300 x 1300 |
| Ask | 1.2800 x 800 |
| Day's Range | 1.1800 - 1.2400 |
| 52 Week Range | 1.1500 - 4.3000 |
| Volume | |
| Avg. Volume | 288,287 |
| Market Cap | 135.467M |
| Beta (5Y Monthly) | -0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7200 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value
Related Research
GlobeNewswireOptinose to Present at the Jefferies Healthcare Conference
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be avail
Simply Wall St.US$4.17: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
Shareholders might have noticed that OptiNose, Inc. ( NASDAQ:OPTN ) filed its quarterly result this time last week. The...
ZacksOptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy spe
- GlobeNewswire
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused
- GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern TimeYARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2023 and corporate updates, before market open on Thursday, May 11, 2023. Company to Host Conference CallMembers of the Company’s leadership team will host a confe
- Simply Wall St.
OptiNose, Inc.'s (NASDAQ:OPTN) Business Is Trailing The Industry But Its Shares Aren't
With a median price-to-sales (or "P/S") ratio of close to 3.1x in the Pharmaceuticals industry in the United States...
- GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incen
- GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will
Insider MonkeyOptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Good day and thank you for standing by. Welcome to the OptiNose’s Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. . Please be advised that today’s […]
- Simply Wall St.
We're Not Very Worried About OptiNose's (NASDAQ:OPTN) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
ZacksOptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical
ZacksSilence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern TimeYARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2022 and corporate updates, before market open on Tuesday, March 7, 2023. Company to Host Conference CallMembers of the Company’s leadership team will host a con
American City Business JournalsBucks County firm seeks to expand approval for flagship product
Optinose is seeking a larger audience for its flagship product. The Bucks County pharmaceutical company has submitted a supplemental new drug application with the Food and Drug Administration for Xhance, which would expand its label to include its use as a treatment for chronic rhinosinusitis. Xhance nasal spray is a drug device combination product that combines an anti-inflammatory drug with the company's proprietary Exhalation Delivery System designed to deliver drugs high and deep into nasal passages.
GlobeNewswireOptinose Submits Supplemental New Drug Application for XHANCE Label Expansion
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE® (fluticasone propionate) nasal spray is a drug device combination product combining an anti-inflammatory drug wit
American City Business JournalsOptinose CEO Peter Miller resigns after 13 years; successor named
The 23-year-old company is getting ready to seek FDA approval to use its lead product for a second indication with a larger patient population.
- GlobeNewswire
Optinose Announces CEO Transition and Business Update
Ramy Mahmoud, MD, MPH appointed CEO and to the Board of DirectorsYARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a
- Simply Wall St.
OptiNose, Inc.'s (NASDAQ:OPTN) top owners are private equity firms with 37% stake, while33% is held by institutions
To get a sense of who is truly in control of OptiNose, Inc. ( NASDAQ:OPTN ), it is important to understand the...
- GlobeNewswire
Optinose Appoints Paul Spence as Chief Commercial Officer
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 year
- GlobeNewswire
Optinose Announces Departure of Acting Chief Financial Officer
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting Chief Financial Officer until her departure on December 30, 2022. Chief Executive Officer Peter Miller stated “On behalf of our enti
- GlobeNewswire
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis Revised Note Purchase Agreement Extends Start of Amortization to September 2025 YARDLEY, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today provided corporate updates and announced that CEO Peter Miller will participate in a